Core Insights - The article highlights the significant presence of leading brands at the analytica2026 event, showcasing innovative products and solutions, reflecting the professional strength and brand image of the industry [2][3]. Industry Overview - The 29th analytica2026 exhibition took place in Munich, Germany, on March 24, 2026, marking the largest and oldest professional exhibition in the field of analytical science, biotechnology, and laboratory technology since its inception in 1968 [3]. - The event attracted 1,141 exhibitors globally, with Chinese exhibitors reaching a record high of 177, representing a growth of over 70% compared to 2024 and nearly threefold compared to 2022, indicating the rise of the Chinese analytical instrument industry and the determination of domestic brands to expand internationally [3]. Domestic Companies - Numerous benchmark Chinese companies showcased core products and innovative solutions, gaining widespread attention from global users and becoming the backbone of domestic instruments going abroad [4]. - Companies like Haineng Future Technology Group, Beijing Beifen Ruili Analytical Instrument Group, and Anhui Wanyi Technology Co., Ltd. presented advanced technologies and reliable quality, contributing to the international competitiveness of Chinese brands [8][11][14]. International Participation - The event also featured many top international instrument manufacturers, fostering a competitive and collaborative atmosphere that promotes technological advancement and industrial upgrading in the global laboratory sector [59]. - Notable international companies included Anton Paar, Bruker, and HORIBA, which are recognized leaders in precision analytical instruments and have a significant global presence [60][66][84]. Product Innovations - Various companies introduced innovative products, such as Beijing Leibotai Technology's integrated solutions for sample preparation and organic analysis, and Qingdao Shenghan Chromatography Technology's advanced ion chromatography instruments [19][38]. - The exhibition served as a platform for companies to demonstrate their technological advancements and engage with global researchers, enhancing the visibility of domestic products in the international market [38][59].

培训情况报告 华泰联合证券有限责任公司关于 广东广康生化科技股份有限公司持续督导期 2025年培训情况报告 深圳证券交易所： 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐人"）作为 广东广康生化科技股份有限公司（以下简称"广康生化"、"公司"）首次公开发 行股票并在创业板上市的保荐人，根据《深圳证券交易所上市公司自律监管指引 第 13 号——保荐业务》《深圳证券交易所创业板股票上市规则》和《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法规和规则 的相关规定以及广康生化的实际情况，认真履行保荐人应尽的职责，对广康生化 的董事、高级管理人员、中层以上管理人员及上市公司控股股东和实际控制人等 相关人员进行了有计划、多层次的 2025 年度持续督导培训培训，所培训的内容 严格按照中国证券监督管理委员会及深圳证券交易所有关持续督导的最新要求 进行。 一、培训的主要内容 2026 年 3 月 5 日，培训小组通过采取现场授课与线上授课相结合的方式对 公司董事、高级管理人员、中层以上管理人员及上市公司控股股东和实际控制人 等相关人员培训。本次培训重点介绍了 2025 年中央经济 ...

Investment Rating - The report maintains an investment rating of "in line with the market" for the basic chemical industry [3]. Core Insights - In February 2026, the CITIC Basic Chemical Industry Index rose by 5.91%, outperforming the Shanghai Composite Index by 4.82 percentage points and the CSI 300 Index by 5.82 percentage points, ranking 6th among 30 CITIC primary industries [3][7]. - The report highlights a continued recovery in chemical product prices, driven by geopolitical tensions in the Middle East, which have led to significant increases in oil prices [3][29]. - The investment strategy for March 2026 suggests focusing on two main lines: organic silicon, pesticides, coal chemical, light hydrocarbon chemical, and calcium carbide-based PVC sectors [3]. Market Review - The CITIC Basic Chemical Industry Index has increased by 57.36% over the past year, outperforming the Shanghai Composite Index by 32.01 percentage points and the CSI 300 Index by 36.27 percentage points, ranking 4th among 30 CITIC primary industries [3][7]. - In February 2026, 28 out of 33 CITIC tertiary sub-industries saw price increases, with the phosphate fertilizer and phosphate chemical, inorganic salt, and soda ash industries leading with increases of 12.82%, 12.69%, and 10.59% respectively [9]. - Among 529 stocks in the basic chemical sector, 391 stocks rose while 136 fell, with Jinzhengdai, Baichuan Co., and Honghe Technology leading the gainers [9][11]. Product Price Tracking - In February 2026, international oil prices showed an upward trend, with WTI crude oil rising by 2.78% to $67.02 per barrel and Brent crude oil increasing by 2.53% to $72.48 per barrel [3]. - Among 318 tracked products, 141 saw price increases, with notable rises in products like tetrachloroethylene and lithium carbonate, while 110 products experienced price declines [3]. Industry and Company News - The report notes that the chemical raw materials and products manufacturing industry saw a year-on-year price decline of 5% in January 2026, indicating ongoing challenges in the sector [14]. - The report also discusses the strategic developments in the Inner Mongolia region, aiming to create a trillion-level chemical industry cluster and a modern coal chemical industry chain [19][20]. - The report highlights the successful launch of a commercial silicon-based immersion cooling project by Xin'an Co., showcasing the potential of organic silicon materials in new applications [22][23].

证券代码：300804 证券简称：广康生化 公告编号：2026-005 广东广康生化科技股份有限公司 关于特定股东减持计划实施完毕的公告 共青城瑞宏凯银壹号股权投资基金合伙企业（有限合伙）保证向本公司提供 的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 二、其他相关说明 广东广康生化科技股份有限公司（以下简称"公司"）于 2026 年 2 月 12 日在巨 潮资讯网（www.cninfo.com.cn）披露了《关于特定股东减持股份的预披露公告》（公 告编号：2026-004），公司股东共青城瑞宏凯银壹号股权投资基金合伙企业（有限合 伙）（以下简称"瑞宏凯银壹号"）拟自减持计划公告披露之日起三个交易日后的三 个月内（即 2026 年 2 月 25 日-2026 年 5 月 24 日）以集中竞价交易或大宗交易方式减 持公司股份累计不超过 1,980,000 股，即不超过公司总股本的 2.6757%。 2026 年 2 月 27 日，公司收到上述股东出具的《关于股份减持计划实施完毕的告 知函》。截至 2026 年 2 月 26 日 ...

Group 1 - The core point of the news is that Guangkang Biochemical conducted a block trade of 130,000 shares on February 27, with a transaction value of 5.9345 million yuan, accounting for 1.49% of the total transaction volume for the day, and the transaction price was 45.65 yuan, which represents a discount of 13.39% compared to the market closing price of 52.71 yuan [1][2] Group 2 - On February 27, 2026, Guangkang Biochemical's stock was traded at a price of 45.65 yuan per share, with a total volume of 70,000 shares, resulting in a total transaction amount of 3.1955 million yuan from the first buyer [2] - Another transaction on the same day involved 60,000 shares at the same price of 45.65 yuan, leading to a total transaction amount of 2.7390 million yuan from a different buyer [2]

Core Viewpoint - The company Guangkang Biochemical announced a share reduction plan by specific shareholders, which may indicate a potential shift in investor sentiment and could impact the stock price in the near term [1][10]. Shareholder Reduction Plans - Specific shareholders, including Huatuo Zhiying No. 2, Huatuo Zhiyuan No. 3, and Ruihong Kaiyin No. 1, plan to reduce their holdings within three months from the announcement date through centralized bidding and block trading [1][4]. - Huatuo Zhiying No. 2 and Huatuo Zhiyuan No. 3 plan to collectively reduce up to 1.3198 million shares, accounting for 1.7835% of the total share capital, while Ruihong Kaiyin No. 1 plans to reduce up to 1.98 million shares, representing 2.6757% of the total share capital [4][6]. Historical Context of Share Reductions - The shareholders are preparing for a "clearance-style" reduction, with Ruihong Kaiyin No. 1 having previously announced a similar reduction plan in October 2025, which was not executed [7]. - Huatuo Zhiying No. 2 and Huatuo Zhiyuan No. 3 had also announced a reduction plan in September 2025, resulting in a decrease in Huatuo Zhiyuan No. 3's holding from 0.6022% to 0.5884% [7]. Company Background - Guangkang Biochemical is a national high-tech enterprise specializing in the research, production, and sales of pesticide active ingredients, intermediates, and formulations [8]. - The company received a warning letter from the Guangdong Securities Regulatory Bureau a month prior to the announcement of the share reduction [10]. Financial Management Issues - From July 2023 to August 2025, the company used raised funds for cash management, purchasing 179 financial products, of which 158 were non-principal guaranteed products. The company did not adequately disclose the risks associated with these investments in its reports [10]. Stock Performance - The timing of the reduction announcement coincides with a nearly 20% rebound in the company's stock price from February 6 to February 11. Following the announcement, the stock initially dipped but later rebounded, closing up over 5% [10].

Core Viewpoint - Guangkang Biochemical (300804.SZ) announced that specific shareholders plan to reduce their holdings in the company through centralized bidding and block trading within three months from the announcement date [1] Group 1: Shareholder Reduction Plans - Shareholders Huatuo Zhiying No. 2 Investment Partnership and Huatuo Zhiyuan No. 3 Investment Enterprise plan to collectively reduce their holdings by no more than 1.3198 million shares, which accounts for 1.7835% of the company's total share capital [1] - Shareholder Ruihong Kaiyin No. 1 Equity Investment Fund plans to reduce its holdings by no more than 1.98 million shares, representing 2.6757% of the company's total share capital [1]

Group 1 - Guangkang Biotech (300804.SZ) announced that specific shareholders, including Qiongcheng Huatuo Zhiying No. 2 Investment Partnership (Limited Partnership), Shenzhen Huatuo Zhiyuan No. 3 Investment Enterprise (Limited Partnership), and Qiongcheng Ruihong Kaiyin No. 1 Equity Investment Fund Partnership (Limited Partnership), plan to reduce their holdings in the company within three months from the date of the announcement [1] - Huatuo Zhiying No. 2 and Huatuo Zhiyuan No. 3 plan to collectively reduce their holdings by no more than 1.3198 million shares, which accounts for 1.7835% of the company's total share capital [1] - Ruihong Kaiyin No. 1 plans to reduce its holdings by no more than 1.98 million shares, representing 2.6757% of the company's total share capital [1]

Group 1 - The core point of the article is that Guangkang Biochemical announced the pledge of 1 million shares by its controlling shareholder, Cai Danqun, to Shenzhen Shendan Credit Financing Guarantee Co., Ltd. for personal funding needs [2] - The pledged shares represent 3.87% of Cai Danqun's total holdings and 1.35% of the company's total share capital [2] - The registration date for the pledge is February 10, 2026 [2]

Group 1 - The core announcement from Guangdong Guangkang Biochemical Technology Co., Ltd. involves specific shareholders planning to reduce their stakes in the company through centralized bidding and block trading within three months from the announcement date [1] - The shareholders, including Qiongcheng Huatuo Zhiying No. 2 Investment Partnership and Shenzhen Huatuo Zhiyuan No. 3 Investment Enterprise, plan to collectively reduce their holdings by up to approximately 1.7835% of the total share capital, which amounts to about 132,000 shares [1] - Another shareholder, Qiongcheng Ruihong Kaiyin No. 1 Equity Investment Fund Partnership, intends to reduce its stake by up to 198,000 shares, representing about 2.68% of the total share capital [1] Group 2 - The news also highlights a significant development in the video generation industry, where a Chinese video model is being referred to as the "strongest on earth," capable of generating 15-second videos for commercial delivery with just a few prompts [1] - This advancement has led to a surge in stock prices for film and television companies, indicating a positive market reaction to the technological innovation [1]